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Abstract 
Overactive bladder (OAB) is a symptom syndrome of urinary urgency, frequency, nocturia, and 
urge incontinence suggestive of lower urinary tract dysfunction. Detrusor overactivity (DO) 
during urodynamic testing may be the cause of symptoms in 54-70% of OAB study participants. 
The identification of urinary biomarkers is warranted due to the high false negative rate of 
urodynamic testing results for the diagnosis of DO and for the evaluation of treatment response 
in study participants with OAB symptoms.  
We reviewed the published literature on urinary biomarkers under investigation for OAB with 
Pub Med up to June 2015 using search keywords that included: “overactive bladder”, “nerve 
growth factor (NGF)”, “brain derived nerve growth factor (BDNF)”, “prostaglandins”, 
“cytokines” and “CRP”.   
Current evidence suggests that NGF and BDNF appear to be most promising candidates for 
urinary biomarkers for the diagnosis and the evaluation treatment response. 
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Introduction 
Overactive bladder (OAB) is not a disease entity but a conglomerate of complex storage 
symptoms characterized by “urinary urgency, usually accompanied by frequency and nocturia, 
with or without urge incontinence in the absence of proven infection or other obvious 
pathology”, suggestive of lower urinary tract dysfunction [1-2]. The pathological sensation of 
urinary urgency is the key symptom of the overactive bladder syndrome.  
The diagnosis of OAB is based on the clinical evaluation of the patient’s symptoms. The 
minimum requirements for the diagnosis include a history, physical examination and urinalysis 
[3]. This evaluation is often used as a basis for initial treatment. Detrusor overactivity (DO) is 
the occurrence of involuntary detrusor contractions of variable amplitude and duration during 
urodynamic testing [2] and may be the cause of symptoms in 54-70% of OAB study participants 
[4].  
The quest for the identification of relevant urinary biomarkers with high sensitivity is warranted 
due to the low sensitivity (high false negative rate) of urodynamic testing results for the 
diagnosis of DO in study participants with OAB symptoms. A deeper knowledge of the 
mechanisms of urinary urgency may help shed light on the pathophysiology of OAB.  
Mechanisms of Urgency 
Physiologic filling signals from the bladder are relayed to the spinal cord by afferent myelinated 
Aδ fibers and non-myelinated C- fibers running in the hypogastric, pelvic and pudendal nerves. 
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The Aδ fiber endings are located in the detrusor smooth muscle layer.  They are tension 
receptors and are considered to be the primary mediator of the physiologic sensation of 
bladder filling when activated. The C- fiber nerve endings are found in the urothelium and the 
lamina propria [5].  They are activated by distention as the bladder nears functional capacity, 
therefore the threshold for C- fiber activation is greater than Aδ fiber activation, because of 
their smaller fiber diameter and non-myelination. The normal micturition reflex is initiated by 
signals from the Aδ fibers. The C- fibers are not essential for normal voluntary voiding [6].  
C fibers can become more mechanosensitive under certain pathologic conditions, leading to 
urinary urgency and detrusor overactivity.  Disease induced changes in C fiber afferent nerve 
excitability and reflex bladder activity is mediated by neurotrophins [7]. 
Neurotrophins are growth factors required by the nerve cells for the survival, maintenance and 
differentiation of sensory and sympathetic neurons. There are four members of the 
neurotrophin family: nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). Neurotrophins act via the family of 
tyrosine kinase receptors (Trk), with TrkA receptors having an affinity only for NGF and TrkB 
receptors having an affinity for BDNF [8].  
Biomarkers 
Biomarkers are biological indicators that can be objectively measured and evaluated. These 
indicators can be used to ascertain the presence of a specific disease entity (diagnostic 
biomarkers), assess its severity or progression (prognostic biomarkers) and evaluate its 
response to a particular treatment (predictive biomarkers) [9]. The use of urinary biomarkers in 
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the diagnosis and the evaluation of treatment response in patients with OAB remains 
controversial because their clinical value is unclear.  Biomarkers have been used to better 
elucidate the different pathophysiological processes involved in the development of this 
syndrome and the pharmacological response to therapeutic modalities.   
There are several biomarkers that are currently under investigation for OAB including the 
aforementioned urinary neurotrophins – nerve growth factor (NGF) and brain derived 
neuropathic factor (BDNF), as well as prostaglandins and cytokines (Table 1). 
Table 1. Strength of Evidence 
Biomarker Diagnostic Prognostic Reference 
NGF *** *** 12,13,14,15,16,17,18,19,20 
BDNF ** ** 13, 25 
sPGE2 ** ** 32, 33, 34, 35 
CRP * * 36, 37, 38, 40 
CXCL-1/ CXCL-10 * * 39, 40 
 
Urinary Nerve Growth Factor  
NGF is a signaling protein that is expressed widely in various cells outside the nervous system. 
In the urinary tract it is produced by bladder urothelium and smooth muscle [10]. NGF can 
affect a wide variety of cell types in the bladder but the majority of research has focused on the 
effects of NGF levels on bladder afferent fibers. Inflammation, spinal cord injury, denervation 
and mechanical stretch, have been shown to cause a rise in bladder NGF levels [11].  
Multiple studies have been performed in humans, in an attempt to better understand the link 
between urinary NGF levels and lower urinary tract symptoms. Liu et al. correlated urinary NGF 
levels with age, BMI, menopausal status, and OAB-wet OAB-dry patient symptomatology. The 
6 
 
urinary nerve growth factor/creatinine (NGF/Cr) levels were noted to be significantly higher in 
the OAB-wet sub-group (2.13 ± 3.87) compared to the OAB-dry sub-group (0.265 ± 0.59) and 
the control group (0.07 ± 0.21). Urinary NGF/Cr was not significantly correlated with age (P = 
0.088) or BMI (P = 0.886) in women with OAB-dry and OAB-wet [12].  
It has been demonstrated that urinary NGF/Cr levels in healthy individuals are consistently low, 
do not exhibit circadian variation and demonstrate no significant difference between the 
genders [13]. Urinary NGF increased physiologically in normal subjects at urge to void but 
remained pathologically elevated in OAB study participants at small bladder volumes without a 
significant increase at urge sensation.  Urine samples were collected at the first sensation of 
bladder filling (FSF) and at urge sensation (US) in 39 study participants with OAB and 35 
controls without lower urinary tract symptoms. Urinary NGF/Cr levels in controls were low at 
FSF (0.011 ± 0.008) and were significantly higher at US (0.086 ± 0.022, p = 0.005). Study 
participants with OAB had significantly higher urinary NGF/Cr levels at both FSF (0.45 ± 0.13, p = 
0.001) and US (1.00 ± 0.32, p = 0.004) compared to controls. The difference in urinary NGF/Cr 
levels between FSF and US in OAB study participants, however, was not significant (p = 0.064) 
[14]. 
A study by Chuang revealed that urinary NGF/Cr did not reflect changes in bladder conditions 
based on subjective symptoms but reflected dynamic changes in bladder pathophysiology 
based on urodynamic findings in study participants who had not been treated for lower urinary 
tract symptoms in the last 3 months [15].  There was no significant difference in urinary NGF/Cr 
showed no significant difference among study participants with improved, stable or worse 
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bladder conditions based on overactive bladder or urgency symptom severity scale scores. 
However, urinary NGF/Cr was significantly decreased in study participants with an improved 
urodynamic diagnosis (mean 0.94 ± 1.36 vs. 0.17 ± 0.19 pg/mg, p=0.02), significantly increased 
in study participants with a worse urodynamic diagnosis (0.55 ± 0.85 vs. 2.08 ± 2.81 pg/mg, 
p=0.04) and showed no change in those with a stable urodynamic diagnosis (0.98 ± 2.31 vs. 0.97 
± 1.89 pg/mg, p=0.99).   
The use of urinary NGF levels as a potential biomarker for DO was investigated in women with 
mixed urinary incontinence (stress urinary incontinence with coexistent urge urinary 
symptoms). Urinary NGF was measured in 38 women with mixed urinary incontinence, 26 
women with urodynamic DO only, 21 women with persistent USI after continence surgery, 15 
women with de novo DO after continence surgery, and 31 control subjects. The urinary NGF/Cr 
levels were low in women with pure USI, and significantly higher in women with USI and 
coexistent DO. The urinary NGF/Cr in the mixed urinary incontinence group was similar to the 
levels in women with pure DO. The NGF/Cr levels were undetectable in women with persistent 
USI but were significantly higher in those with de novo DO after continence surgery. A urinary 
NGF/Cr level of > 0.05 was found in 9% of women with USI, 77% with DO, 81% with mixed USI 
and coexisitent DO, and 80% with de novo DO. This study indicated that NGF could be a 
potential biomarker for the presence of DO in women with mixed etiologies [16].  
Improving OAB symptoms as measured by the urgency severity scale (USS) correlated with 
declining urinary NGF/Cr levels in responders to anticholinergic treatment validating NGF/Cr as 
a potential predictive urinary biomarker. Liu et al. measured urinary NGF levels in 38 controls 
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and 70 study participants with OAB symptoms. Study participants with OAB symptoms were 
treated with tolterodine 4 mg once daily. NGF/Cr levels and USS scores were compared at 
baseline, 1, 2 and 3 months after tolterodine and 1 month after cessation of treatment. Urinary 
NGF/Cr levels were significantly reduced at 3 months in 50 responders (1.10 ± 0.26 before vs. 
0.41 ± 0.09 after, p = 0.008) but not in the 20 non-responders (1.38 ±0.54 before vs. 1.30 ± 0.46 
after, p = 0.879). After anti-cholinergic treatment cessation, the urinary NGF/Cr level was 
elevated in 23 responders (0.83 ± 0.33) and in five non-responders (2.72 ± 1.41) [17].  
Chronic inflammation from systemic illness and medical co-morbidities may play a role in the 
pathogenesis of OAB through its effect on circulating levels of serum NGF. Lui et al investigated 
correlations between serum NGF levels in study participants with OAB refractory to 
anticholinergic therapy, with and without concurrent medical co-morbidities [18]. Serum NGF 
levels were significantly higher in study participants with OAB and chronic medical co-
morbidities (4.65 ±4.21, p=0.014) compared with controls (2.57 ± 0.88), but not in study 
participants with OAB without concurrent chronic medical co-morbidities (2.88 ± 0.62, 
p=0.621). 
Urinary NGF levels as a potential predictive urinary biomarker was studied in study participants 
with DO before and after treatment with intra- detrusor botulinum toxin A (BoNT-A) injections 
[19]. Urinary NGF levels were measured in 143 study participants with idiopathic DO (IDO) and 
100 with neurogenic DO (NDO) who were untreated, well-treated, and failed-treatment with 
antimuscarinics.  Detrusor injections of BoNT-A (100 U for IDO, 200 U for NDO) were given to 24 
study participants with IDO and 19 with NDO who had failed antimuscarinic treatment.   Thirty-
eight participants without lower urinary tract symptoms served as controls. The urinary NGF/Cr 
9 
 
levels in study participants with DO at baseline and 3 months after BoNT-A injection were 
compared  to controls. . The mean urinary NGF/Cr levels were significantly higher in 66 study 
participants with untreated IDO (1.44 ± 2.66, p <0.001) and in the 59 with untreated NDO (0.62 
± 1.22, p <0.001) compared to controls (0.005 ± 0.019). Study participants  with well-treated 
IDO or NDO had reduced NGF/Cr levels, compared to those with failed-treatment IDO or NDO 
did not. Study participants who responded to BoNT-A treatment had significantly reduced 
urinary NGF/Cr levels in both the IDO (0.07 ± 0.12, p=0.025) and NDO (0.096 ± 0.17, p=0.033) 
groups compared to baseline levels. However, the NGF levels remained significantly higher at 3 
months in 7 IDO (1.01 ± 1.25) and 5 NDO (1.64 ± 2.39) study participants who failed BoNT-A 
treatment.  
Shalom studied the use of urinary NGF as a potential predictive biomarker for assessment of 
the therapeutic response to peripheral nerve evaluation (PNE).  Urinary NGF and creatinine 
levels in 23 study participants with symptomatic DO who failed anticholinergic treatment  were 
compared to controls at baseline and 5 days after a PNE trial.  Study participants with DO had 
significantly higher baseline urinary NGF levels (corrected for creatinine) compared with 
controls (19.82 pg/mg vs 7.88 pg/mg, P < .002).  Urinary NGF levels significantly decreased from 
17.23 pg/mg to 9.24 pg/mg (P < .02) after PNE in symptomatic DO study participants [20].  
Urinary NGF levels are higher in study participants with OAB and are responsive to change after 
effective therapy making it an attractive candidate for both a diagnostic and predictive urinary 
biomarker.  However, NGF has also been shown to be elevated in study participants with acute 
bacterial cystitis, urinary tract stones or urothelial cell carcinoma that were not associated with 
10 
 
the presence of OAB symptoms suggesting a low test specificity [21]. As a result, care must be 
taken to exclude these other etiologies prior to a diagnosis of OAB being made.  
Brain-Derived Nerve Growth Factor 
Brain-derived neurotrophic factor (BDNF) is a tissue-derived trophic protein that is found 
abundantly in the central nervous system. Its synthesis occurs in small-to-medium dorsal root 
ganglia and stored in dense-core synaptic vesicles. There is growing evidence to suggest that 
BDNF plays an important role in pain and inflammatory processes. Noxious stimuli have been 
shown to induce the release of BDNF in the dorsal horn of the spinal cord [22] and intra-thecal 
injection of BDNF has been shown to decrease the threshold to noxious stimuli [23]. In addition, 
it has been shown that intrathecal injections of NGF increased BDNF levels in a sub-population 
of cells that expressed the TrkA receptor [24]. Studies investigating the role of BDNF in bladder 
inflammation and potentially OAB have been conducted given its involvement in pain and 
inflammatory processes.  
Wang et al [25] compared the diagnostic performance of urinary BDNF to NGF in 90 study 
participants diagnosed with OAB based on the International Continence Society criteria.  
Results revealed that BDNF/Cr and NGF/Cr levels were increased in the 90 OAB women 
compared with controls (BDNF/Cr: 11.95 vs. 1.65, p<0.001; NGF/Cr: 0.15 vs. 0.08, p< 0.001). 
There was an 80-fold magnitude difference between BDNF/Cr  and NGF/Cr levels in study 
participants with OAB and yet there was still a significant positive correlation between both 
BDNF/Cr  and NGF/Cr levels and symptom severity, as measured by an overactive bladder 
symptom scale.   The sensitivity (88.9%) and specificity (100.0%) of tests measuring urinary 
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BDNF/Cr levels (cut off at ≥ 4.6) were significantly higher than tests measuring NGF/Cr 
levels(cut off at ≥ 0.14, sensitivity: 54.4 % and specificity: 95.6%) for the diagnosis of OAB in 
symptomatic women.  
Antunes- Lopes et al [13] compared urinary NGF and BDNF levels in treatment naïve study 
participants with OAB after non-pharmacologic and pharmacologic interventions to determine 
whether lifestyle modification had an influence on urinary neurotrophic factor levels. After 
lifestyle modifications there was a non-significant decrease in NGF/Cr (mean 488.5 ± 591.8 to 
319.7 ± 332.3, p = 0.318) but a significant decrease in BDNF/Cr (mean 628.1 ± 590.5 to 432.5 ± 
589.0, p = 0.033) compared to pre-treatment levels. After anticholinergic treatment the NGF/Cr 
and BDNF/Cr levels further decreased to a mean of 179.8 ± 237.9 and 146.6 ± 264.9 (vs baseline 
p = 0.008 and <0.001, respectively). 
The use of BDNF as a potential urinary biomarker is promising.  BDNF levels are higher in study 
participants with OAB and tests measuring BDNF/Cr levels are responsive to change after 
treatment.  The superior diagnostic performance of BDNF relative to NGF may substantiate its 
use as a more effective diagnostic and predictive urinary biomarker.  However, caution must be 
used when interpreting these results as BDNF has been investigated as a marker in PBS/ ICS (26, 
27, and 28) suggesting a role as a chronic inflammation predictor.  
Prostaglandins 
Prostaglandins (PG) are autacoids that are derived from fatty acids (arachidonic acid) that act 
like local hormones with a brief duration near the site of synthesis.   They are responsible for 
and implicated in a wide range of physiological events and pathological mechanisms.  There are 
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four principle types of PG’s: PGE2 (responsible for arterial dilation and vascular permeability), 
PGF2A (vasoconstriction), PGD2 (produced by mast cells and in the CNS and plays a role in pain 
perception), and prostacyclin (potent vasodilator and inhibitor of platelet aggregation).  PGs are 
locally synthesized in the detrusor muscle and mucosa. This synthesis is influenced and initiated 
by smooth muscle stretch, nerve stimulation, mucosal damage and inflammatory mediators. 
PGs are implicated in the premature activation of the normal micturition reflex by decreasing 
the threshold of the stimuli necessary to trigger a bladder contraction through capsaicin 
sensitive afferent nerve stimulation [29, 30, and 31] 
PG may be increased in study participants with OAB and as a result may have the potential to 
be used a diagnostic urinary biomarker.   Kim et al [32] investigated the effect of pathological 
changes in the bladder (OAB) on urinary levels of PG’s and NGF in sixty-five women with OAB 
compared to twenty without bladder symptoms. Urinary PGE2 and PGF2α were significantly 
increased in study participants with OAB compared with controls (1.54 ± 0.15 and 0.94 ± 0.17 
versus 0.45 ± 0.15 and 0.28 ± 0.10, respectively, p < 0.05). There was no statistical difference in 
urinary PGI2 levels in OAB study participants compared to controls. Urinary PGE2 levels were 
positively correlated with volume at first desire to void and maximum cystometric capacity 
(r=0.445, p < 0.05) in study participants with OAB suggesting that generation of PG’s can be 
induced by bladder stretching and distention.  
Liu et al [33] investigated whether the measurement of PGE2 levels could differentiate between 
study participants with OAB and ICS/PBS syndromes. Urinary PGE2/Cr levels did not differ 
between study participants with DO based on urodynamic results, over active bladder 
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symptoms without urodynamic evidence, and interstitial cystitis/bladder pain 
syndrome(IC/BPS) compared to controls.  
Cho et al. [34] investigated the effect of anticholinergic treatment on changes in urinary NGF 
and PGE2 levels in thirty study participants with OAB compared to fifteen healthy women.  
Urinary NGF and PGE2 levels were significantly higher in OAB study participants than in the 
controls. However, tests measuring PGE2 levels were not responsive to change after treatment 
with anticholinergics.  
Hegele et al [35] analyzed PGE2 blood levels (sPGE2) in study participants with OAB before and 
4 weeks after BoNT-A therapy.  Significantly higher sPGE2 levels were detected in study 
participants with OAB compared to the control group (2750 pg/ml vs. 1674 pg/ml, p < 0.005). In 
study participants treated with BoNT-A, sPGE2 levels decreased after treatment (2995 pg/ml 
versus 486 pg/ml, p <0.005). Decrease in sPGE2 levels were positively correlated with the mean 
duration of drug effect (9 month). Study participants with a shorter drug effect (< 9 months) 
had less of a sPGE2 decrease compared to study participants with a drug effect > 9 months 
(22.2% vs. 57.4% decrease, p< 0.05). There were 3 non-responders to BoNT-A, 2 of which had 
an increase in their sPGE2 levels of 51% compared to baseline.  
While urinary PG levels were elevated in study participants with OAB, their use as potential 
diagnostic and prognostic urinary biomarkers is hindered by the lack of difference in study 
participants with OAB and ICS/PBS and responsiveness to change after treatment. The use of 
sPGE2 as a diagnostic and predictive urinary biomarker seems promising. 
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C reactive protein and Cytokines 
C- reactive protein (CRP) is a pentameric plasma protein that is produced by hepatocytes. It is 
an acute phase reactant that increases after the secretion of interlukin-6 from macrophages 
and T cells serving as a marker for inflammation. Cytokines are a group of small proteins 
released by cells for signaling behavior change in neighboring cells in response to infection, and 
inflammation.  CRP and cytokines have been investigated as potential biomarkers for lower 
urinary tract symptoms because chronic inflammation has been implicated in the development 
of OAB and ICS/PBS [36].  
Chung et al [37] measured serum CRP and urinary nerve growth factor (NGF) levels in 22 study 
participants with OAB, and 48 study participants with IC/BPS compared to controls. Serum CRP 
levels were significantly higher in subjects with OAB (1.83 ± 2.30 mg/L vs. 0.59 ± 0.40 mg/L, 
p=0.012) compared to controls but there was no significant difference in CRP level between 
study participants with OAB and IC/BPS (p=0.43). While CRP levels were elevated in study 
participants with OAB, the magnitude of the increase was not suggestive of systemic infection.  
Only 13.6% of OAB and 8.7% of IC/BPS study participants had a clinically significant elevated 
serum CRP level (>3 mg/L), suggesting the inflammatory process in OAB or ICS/PBS is localized.  
Hsiao et al. [38] determined that median CRP levels were significantly higher in women with 
overactive bladder (OAB) wet (0.12 mg/dl) compared to women with bladder hypersensitivity/ 
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OAB dry (0.075 mg/dl, p = 0.008) and controls (0.055 mg/dl, p = 0.032) suggesting a positive 
correlation between serum CRP and severity of symptoms.  
Tyagi et al. [39] investigated the role of select chemokines as a diagnostic biomarker in a sub-
set of study participants with ulcerative and non-ulcerative ICS/PBS. There was a greater than 
tenfold increase in CXCL-1 levels (mean 170 ± 60.55 vs 12.55 ± 3.38 pg/ml) and a fivefold 
increase in CXCL-10 levels (684.7 ± 68.10 vs 123.3 ± 45.35 pg/ml, p <0.001) comparing 
ulcerative to non-ulcerative ICS/PBS cases. There was a similar twentyfold increase in NGF 
(60.82 ± 25.38 vs 3.5 ± 1.6) and a fivefold increase in IL-6 (16.06 ± 6.99 vs 2.42 ± 1.94 pg/ml).  
These findings were further substantiated in a subset of OAB study participants that were 
refractory to previous anti-muscarinic treatment. Liu et al. [40] noted that the serum 
concentrations of CRP, NGF, IL-1β, IL-6, IL-8, and TNF-α in OAB-dry and OAB-wet study 
participants were significantly higher than among the controls. 
The use of CRP and cytokines as potential biomarkers for OAB and ICS/PBS remains debatable. 
While there is a growing body of evidence to suggest that inflammation plays a key role in the 
development of OAB and ICS/PBS, the measurement of CRP and cytokines as urinary 
biomarkers has its limitation because it can be easily influenced by any systemic inflammatory 
process.  
Conclusion 
Our review of urinary neurotrophins (NGF and BDNF), prostaglandins, CRP and cytokines as 
urinary biomarkers of OAB has shed some light on the pathophysiology of OAB and the 
feasibility of their use as diagnostic and prognostic markers.  
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The use of NGF as a reliable diagnostic biomarker is promising since it is sensitive enough to 
distinguish between controls, OAB –dry and OAB –wet study participants. NGF levels mirrored 
urodynamic findings in study participants with OAB revealing significantly higher levels at “first 
sensation” and “urge sensation” compared to controls but did not reflect changes in bladder 
conditions based on subjective symptoms (urge severity scale). In addition, NGF levels 
differentiated study participants with pure USI and and USI with coexistent detrusor 
overactivity.   
The use of urinary NGF as a prognostic biomarker is strengthened by evidence revealing 
significant reduction after anticholinergic treatment in responders compared to nonrespnders.  
This was similarly demonstrated after BoNT-A injections and PNE treatments.  
Though less studied, urinary BDNF has very similar characteristics to urinary NGF with the 
advantage of having more sensitive and specific tests of its measurement for the diagnosis of 
OAB in symptomatic study participants.  The superior diagnostic performance of BDNF relative 
to NGF may validate its use as a more effective diagnostic and predictive urinary biomarker. 
Urinary PGE2 and PGF2α were significantly increased in study participants with OAB compared 
with controls but could not differentiate between study participants with OAB and ICS/PBS 
syndromes.  Furthermore, PGE2 and PGF2α levels were not responsive to change after 
treatment limiting their diagnostic and prognostic value. The use of sPGE2 as a diagnostic and 
predictive urinary biomarker seems promising because of studies demonstrating significantly 
decreased levels after BoNT-A injections in study participants with OAB.  
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Serum CRP levels were significantly higher in subjects with OAB compared to controls but there 
was no significant difference between study participants with OAB and IC/BPS thus limiting 
their diagnostic value. The measurement of CRP and cytokines as urinary biomarkers is limited 
because it can be easily influenced by any systemic inflammatory process. 
In summary, we think that NGF has features that make it a good candidate as a diagnostic and 
prognostic urinary biomarker.  While BDNF is not as extensively studied, its characteristics are 
promising. PG’s, CRP and cytokines have shed light on the pathophysiology of the OAB disease 
process but their inability to distinguish between OAB syndrome and ICS/PBS will limit their 
use.  
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